CAS and AstraZeneca agree to 5-year SciFinder® contract.
Press Release Summary:
February 26, 2014 - Chemical Abstracts Service announced 5-year agreement for SciFinder®, the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. Long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive, and current research, and signifies the confidence customers have in CAS as a high-quality information partner.
Original Press Release
CAS and AstraZeneca Agree to Five-Year SciFinder® Contract
Press release date: February 20, 2014
Agreement with Biopharmaceutical Leader is Indicative of the Longstanding Value of CAS Products
COLUMBUS, Ohio, -- Chemical Abstracts Service (CAS), the world's authority for chemical information, announced today a landmark five-year agreement for SciFinder(®), the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines. The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.
"SciFinder has played an important role in our research into the development of innovative, life-saving medicines," said Steve Rees, VP, Screening Sciences and Sample Management at AstraZeneca. "This partnership will support our worldwide R&D teams with the tools and knowledge they need to advance discoveries that will ultimately make a difference in the lives of patients across the globe."
An early adopter of Enterprise-Wide Pricing, AstraZeneca has relied on SciFinder to meet the needs of its researchers for nearly a decade, and this five-year agreement is a first for SciFinder within the pharmaceutical industry. It signifies the confidence customers have in CAS as a high-quality information partner providing reliable access to the most up-to-date research in the chemical industry and beyond.
"The trust that AstraZeneca shows in SciFinder by entering into this agreement exemplifies that our content spans a multitude of scientific disciplines while maintaining the highest levels of excellence," commented Chris McCue, vice president of marketing at CAS. "Such a long-term contract sends a clear message that SciFinder is a product the biopharmaceutical industry considers essential for its research needs."
Chemical Abstracts Service (CAS), a division of the American Chemical Society, is the world's authority for chemical information. CAS is the only organization in the world whose objective is to find, collect and organize all publicly disclosed substance information. A team of scientists worldwide curates and controls the quality of our databases, which are recognized as the most comprehensive and authoritative by chemical and pharmaceutical companies, universities, government organizations and patent offices around the world. By combining these databases with advanced search and analysis technologies (SciFinder(®) and STN(®)), CAS delivers the most current, complete, secure and interlinked digital information environment for scientific discovery.
CONTACT: Rhonda Ross, 614-447-3624, email@example.com
Web Site: http://www.cas.org